Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice : Episode 7

Video

October 19, 2022

Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

Author(s):

Solange Peters, MD, PhD,Melissa Johnson, MD

Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.

EP: 1.Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

EP: 2.The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

EP: 3.Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

EP: 4.Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

EP: 5.Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial

EP: 6.The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC

Now Viewing

EP: 7.Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

EP: 8.Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

EP: 9.CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

EP: 10.KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

EP: 11.EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

EP: 12.POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

EP: 13.Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

EP: 14.The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

EP: 15.The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

EP: 16.A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

EP: 17.The Exciting Future of NSCLC Treatment

EP: 18.Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?

EP: 19.POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

EP: 20.Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations

EP: 21.Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations

EP: 22.Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512